FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
| (a) Full name of discloser: | Seamus Mulligan (Including Nerano Pharma Limited, Nerano Capital Limited, Barrymore Investments Limited) |
| (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | Seamus Mulligan |
| (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree | Advanced Oncotherapy Plc |
| (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: | N/A |
| (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure | 3rd May 2023 |
| (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | NO
|
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
| Class of relevant security:
| Ordinary Shares of 25p each in Advanced Oncotherapy Plc ("Ordinary Shares") | |||||
|
| Interests | Short positions | ||||
|
| Number | % | Number | % |
| |
| (1) Relevant securities owned and/or controlled: | 30,405,721
| 5.65 | None | N/A |
| |
| (2) Cash-settled derivatives:
| None | N/A | None | N/A |
| |
| (3) Stock-settled derivatives (including options) and agreements to purchase/sell: | None | N/A | None | N/A |
| |
|
TOTAL: | 30,405,721
| 5.65 | None | N/A |
| |
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
| Class of relevant security in relation to which subscription right exists: | Secured Convertible Loan Facility |
| Details, including nature of the rights concerned and relevant percentages: | In June 2020, Advanced Oncotherapy Plc ("AVO") entered into an interest-bearing secured convertible loan facility ("Facility") with Nerano Pharma Limited. Interest accrues at the rate of 5.0% per annum on amounts drawn under the Facility. In 2020, AVO drew down $10.0 million under the Facility. The Facility is secured on various assets of Advanced Oncotherapy plc.
On maturity all amounts drawn under the Facility together with any accrued unpaid interest are repayable by AVO. Under the Facility, AVO may, at its option, repay part, or all, of the loan (together with any accrued interest) prior to the maturity date.
Nerano Pharma Limited, at its option, may convert, into fully paid ordinary shares of AVO at the conversion price of 25 pence per ordinary share, amounts that AVO opts to prepay during the term of the Facility and/or any outstanding loan amounts and interest payable on maturity of the Facility. |
| Class of relevant security in relation to which subscription right exists: | Warrants |
| Details, including nature of the rights concerned and relevant percentages: | · 3,500,000 warrants with exercise price of 100.00p expiring on 7th May 2024 · 5,000,000 warrants with exercise price of 50.00p expiring on 28th June 2025 · 3,750,000 warrants with exercise price of 60.00p expiring on 11th November 2024 · 6,382,978 warrants with exercise price of 28.20p expiring on 24th March 2025 · 5,000,000 warrants with exercise price of 25.00p expiring on 8th November 2027 |
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
| Class of relevant security | Purchase/sale
| Number of securities | Price per unit |
|
|
|
|
|
(b) Cash-settled derivative transactions
| Class of relevant security | Product description e.g. CFD | Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position | Number of reference securities | Price per unit |
| |
| | | |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
| Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates | Exercise price per unit | Type e.g. American, European etc. | Expiry date | Option money paid/ received per unit |
| | | | | | | | |
(ii) Exercise
| Class of relevant security | Product description e.g. call option | Exercising/ exercised against | Number of securities | Exercise price per unit |
|
|
|
|
|
|
(d) Other dealings (including subscribing for new securities)
| Class of relevant security | Nature of dealing e.g. subscription, conversion | Details | Price per unit (if applicable) |
|
|
|
|
|
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
| Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" |
|
None
|
(b) Agreements, arrangements or understandings relating to options or derivatives
| Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" |
|
None
|
(c) Attachments
| Is a Supplemental Form 8 (Open Positions) attached? | No |
Date of disclosure: | 3rd May 2023 |
Contact name: | Declan Brides |
Telephone number*: | +353 87 968 9032 |
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.